Gyre Therapeutics

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$22,519
$37,195
$30,564
$26,771
Gross Profit
21,292
35,452
28,936
25,620
EBITDA
-9,237
629
8,278
2,813
EBIT
-66
7,629
2,172
Net Income
-8,616
-1,723
3,610
442
Net Change In Cash
22,519
37,195
30,564
26,771
Free Cash Flow
3,002
-5,769
3,993
1,809
Cash
37,501
37,070
40,402
36,491
Basic Shares
91,344
102,940
102,701
102,701

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$116,588
$105,757
$113,450
$102,290
Gross Profit
111,172
101,873
108,814
97,497
EBITDA
16,956
17,817
20,327
10,541
EBIT
14,436
16,229
19,213
9,412
Net Income
5,027
12,085
-92,933
2,302
Net Change In Cash
116,588
105,757
113,450
102,290
Free Cash Flow
-180
-6,769
17,306
5,679
Cash
37,070
11,813
33,509
25,175
Basic Shares
103,180
102,293
65,831
75,686

Earnings Calls

QuarterEPS
2026-03-31
-$0.10
2025-12-31
$0.04
2025-09-30
$0.03
2025-06-30
$0.002